Found: 8
Select item for more details and to access through your institution.
Unraveling the role of hepatitis B virus DNA integration in B-cell lymphomagenesis.
- Published in:
- British Journal of Cancer, 2024, v. 131, n. 6, p. 996, doi. 10.1038/s41416-024-02763-y
- By:
- Publication type:
- Article
Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 5, p. 1211, doi. 10.1007/s00432-021-03719-y
- By:
- Publication type:
- Article
Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B‐Cell Lymphoma in the Rituximab Era.
- Published in:
- Oncologist, 2020, v. 25, n. 9, p. 793, doi. 10.1634/theoncologist.2019-0756
- By:
- Publication type:
- Article
A Clinicopathological Study of Cytomegalovirus Lymphadenitis and Tonsillitis and Their Association with Epstein–Barr Virus.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 4, p. 2661, doi. 10.1007/s40121-021-00528-1
- By:
- Publication type:
- Article
Cerebrospinal fluid soluble programmed death‐ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 1, p. 75, doi. 10.1111/bjh.18598
- By:
- Publication type:
- Article
Long‐term outcomes of combined intravitreal methotrexate and systemic high‐dose methotrexate therapy in vitreoretinal lymphoma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 7, p. 8102, doi. 10.1002/cam4.5609
- By:
- Publication type:
- Article
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 2, p. 349, doi. 10.1007/s00277-021-04711-9
- By:
- Publication type:
- Article
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
- Published in:
- 2020
- By:
- Publication type:
- journal article